Meralys (Xylometazoline) is a topical agent used to provide symptomatic relief by addressing pronounced nasal congestion and obstruction. It is applied across domains where acute or episodic swelling causes significant discomfort and hinders normal breathing. The medication is relevant in conditions characterized by periods of heightened symptoms, such as the common cold, hay fever, and episodes of sinusitis.

The medication is commonly used across conditions presenting with acute episodes of nasal congestion, offering support that helps ease the overall symptom burden. It is applied in scenarios where additional management of discomfort is required, assisting with maintaining functional stability when symptoms interfere with routine activities. For example, during a cold or an allergic flare-up: “The therapeutic focus is on easing symptoms that create noticeable physiological strain.”

Therapeutic Scope

Meralys is relevant for managing symptoms associated with nasal blockage that appear suddenly or fluctuate, such as those due to the common cold, allergic rhinitis, and sinusitis.

Quick Fact: Relief for Nasal Obstruction

The primary therapeutic benefit assists with maintaining functional stability, which supports patients during difficult episodes by easing distress.

Regulatory References

1. Health Products Regulatory Authority (HPRA) documentation

Eligibility Map: Who Can and Cannot Use Meralys

The eligibility profile for Meralys (Xylometazoline hydrochloride) is strictly defined by government regulatory documents, outlining populations permitted to use the medicine and those who are formally excluded.

Eligibility Scope	Regulatory Status
Allowed Ages	Adults and adolescents (aged 12+ for 0.1% strength); Children (aged 2–12 years for 0.05% strength).
Contraindicated	Patients with known hypersensitivity to the drug, narrow-angle glaucoma, rhinitis sicca, or a history of trans-sphenoidal surgery.
Absolute Exclusion	Children under 2 years of age; patients currently taking or who have taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Condition-Based Restrictions (Use with Caution) The medicine must be used with caution in patients with conditions that are sensitive to sympathomimetic agents, including hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, Long QT syndrome, phaeochromocytoma, or prostatic hypertrophy.

Pregnancy and Lactation Use during pregnancy is generally not recommended due to the drug's potential for systemic vasoconstrictive effects. Use during breastfeeding requires caution, as regulatory status notes that excretion into breast milk is not known.

Interaction Scope

The interaction profile for Meralys (Xylometazoline) is primarily defined by the drug's classification as a sympathomimetic agent. Due to the very low systemic exposure of the topical nasal formulation, official regulatory documents state that interactions involving metabolic enzymes, such as the cytochrome P450 (CYP) system, are generally not considered clinically significant. The documented interactions are predominantly of a pharmacodynamic nature, where effects on the cardiovascular system are cumulative or antagonistic.

Interaction Classifications (High-Level)

The regulatory basis for Xylometazoline interactions classifies combinations into critical and cautionary categories. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited, requiring a mandatory two-week separation period following the discontinuation of the MAOI due to the risk of a hypertensive crisis. The label also specifies that co-use with Tricyclic and Tetracyclic Antidepressants is not recommended due to the potential for additive blood pressure-raising effects, classifying this combination as requiring extreme caution.

Official Interaction Statements

• The use of Xylometazoline is contraindicated in combination with MAOIs, including for 14 days following their use, as stated in regulatory documentation.
• Combinations with other sympathomimetic medicines may cause cumulative cardiovascular and Central Nervous System (CNS) effects, warranting restriction.
• Official labeling notes that the drug may block the hypotensive effects of certain blood pressure-lowering medicines, such as beta-blockers, due to its vasoconstrictive activity.
• Patients with Long QT Syndrome may face an increased risk of serious ventricular arrhythmias when treated with Xylometazoline, as documented in regulatory warnings.

Connection to the overall interaction profile:

Regulatory documents establish that the interaction structure of Meralys is fundamentally defined by its sympathomimetic activity, leading to pharmacodynamic reinforcement with other stimulatory agents. This profile guides the formal contraindications and not-recommended combinations with specific classes of medicines listed in the official prescribing information.

Xylometazoline is a direct-acting agonist at the alpha-adrenergic receptors (alpha1 and alpha2) expressed on the vascular smooth muscle of the nasal mucosa. This interaction mimics sympathetic nervous system signals, initiating the Gq cascade that elevates intracellular calcium ( Ca^2+) and triggers the contraction of these blood vessels, a physiological process known as vasoconstriction.

The resulting localized vasoconstriction leads to a reduction of the blood volume pooled in the submucosal venous sinusoids. This physical reduction of vascular fluid causes the swollen tissues (oedema) to shrink, which modifies the physical geometry of the nasal airway.

The mechanism of action is subject to receptor desensitization (tachyphylaxis) where prolonged use leads to a functional uncoupling or downregulation of the alpha-adrenoceptors. This constraint results in the attenuation of the vasoconstrictive response and can trigger rebound vasodilation, a compensatory hyperemic response that follows the cessation of intense vasoconstriction.

Official Administration Guidelines

Melatonin 1 mg/ml oral solution, marketed as Meralys, must be administered orally using the provided 10 ml graduated oral syringe and “Press-In” Bottle Adapter (PIBA). No preparation, such as dilution or reconstitution, is required before administration. The medication is delivered into the mouth directly from the syringe.

Usage Context	Dosing Rules	Timing and Conditions
Adults (Jet Lag)	Standard dose is 3 mg (3.0 ml) daily, taken for a maximum of 5 days. The dose may be increased to 6 mg (6.0 ml) if the standard dose is inadequate. The lowest effective dose should be used for the shortest possible duration.	The first dose must be taken upon arrival at the destination at the individual's habitual bedtime. Dosing must not occur before 20:00 hr or after 04:00 hr local time at the destination.
Children/Adolescents (6–17 years with ADHD)	Starting dose is 1–2 mg (1.0–2.0 ml). The dose may be increased by 1 mg (1.0 ml) weekly until effect, up to a maximum daily dose of 5 mg (5.0 ml).	Dosing should be initiated and monitored by a physician experienced in ADHD or pediatric sleep medicine. Treatment effects must be evaluated after at least 3 months.

For all users, it is recommended that food is not consumed two hours before and two hours after taking the oral solution due to potential effects on plasma concentration. Individuals with significantly impaired glucose tolerance or diabetes should take the medicine at least three hours after a meal. Alcohol consumption must be avoided when using the oral solution.

The administration involves a time-specific, dose-titrated daily regimen, requiring precise measurement via the designated oral syringe. The administration is constrained by specific timing relative to sleep/destination time and mandatory meal separation to ensure appropriate use and effect.

Research Evidence / Overview of Studies for Meralys

The clinical evaluation of Meralys primarily relies on findings from short-term clinical trials. These studies, often randomized and controlled, examine the acute effects of the medicine on the physical feeling of nasal blockage and metrics used to objectively measure nasal airflow. The research provides context regarding patient experiences during brief periods of use.

---

Research Evidence for Acute Nasal Congestion (Common Cold)

Researchers used short-term, placebo-controlled Randomized Controlled Trials (RCTs) to study the temporary relief of nasal congestion associated with the common cold. Study outcomes examined both objective physiological measures of the nasal passages, such as nasal conductance, and patient-reported outcomes describing perceived discomfort. Studies reported measurements of nasal airflow that were compared between the study group and the placebo group following administration. Studies monitored metrics related to the time until a change was observed, with some patterns observed to last for several hours.

---

Evidence for Congestion in Allergic Rhinitis and Sinusitis

For allergic rhinitis (e.g., hay fever), the research includes historical controlled studies. Findings described patterns related to a temporary effect on measured nasal swelling compared to a placebo. Research describing a comparison with other topical treatments is not included in some studies, and the evidence is limited regarding long-term allergy management.

For sinusitis, research explored physiological changes in the nasal and sinus lining. Findings described patterns related to a measurable change in nasal airflow and explored outcomes linked to mucosal swelling. Research focusing on outcomes related to the overall clinical course of the condition remains limited.

---

Evidence Gaps and Areas of Uncertainty

Despite the body of research, several aspects remain uncertain. Long-term effects are not fully established, as clinical trials focused only on short, acute usage periods. Consequently, there is limited information about use beyond the temporary recommended duration. Furthermore, data for certain populations remain insufficient, especially infants and very young children.

Key Studies & References

1. The efficacy of xylometazoline, the risk of rhinitis medicamentosa (RM), and treatment strategies: A review of published studies
2. Xylometazoline hydrochloride Summary of Product Characteristics (SPC) - Example Regulatory Document for Pediatric Information

Common questions about Meralys (FAQ)

Q: Is Meralys the same type of medicine as others for this condition?

A: Official product information classifies the active substance in Meralys as a sympathomimetic agent. This means it works by constricting the blood vessels in the nasal lining, a mechanism known as vasoconstriction.

This vasoconstrictor (blood vessel-narrowing) mechanism is different from that of non-decongestant treatments used for the same condition.

Q: Is it okay to take Meralys if I'm taking vitamins or supplements?

A: The regulatory warnings for the active substance indicate the importance of consulting a healthcare professional before treatment if you are currently taking any other medicines.

This caution specifically includes the use of both prescription and non-prescription medicines, as well as herbal and vitamin supplements.

Q: Do older adults use Meralys differently than younger adults?

A: Official patient information for the active substance cautions against exceeding the recommended dosage, especially when the medicine is used by children or elderly individuals.

This caution is documented because older adults, like children, may be more sensitive to the systemic effects of the medication.

Q: Is Meralys a habit-forming medicine?

A: Based on regulatory-related safety information, the active substance has not been reported to cause habit-forming tendencies.

However, official information notes that frequent or prolonged use of nasal decongestants can lead to 'rebound congestion,' a condition where the nose becomes more blocked after the medication is stopped.

Q: What is the time period Meralys typically stays effective for after taking it?

A: Studies and official product information indicate that the decongestant effect of the active ingredient typically begins very quickly, within minutes of application.

The duration of this effect is documented to last for an extended period, generally for up to 12 hours.

Q: Is Meralys ever used alongside other prescribed treatments?

A: Regulatory documents primarily detail specific medicines that are prohibited or require caution when used with Meralys.

Co-administration with non-listed medicines is generally considered after a professional review of the patient's full medical profile.

Q: Do studies suggest Meralys is better for some symptoms than others?

A: Clinical studies have investigated the active substance regarding various symptoms of the common cold.

Research patterns were observed regarding the temporary relief of individual cold symptoms, such as making breathing easier, in addition to general nasal congestion.

Q: How common is it to experience a rare side effect from Meralys?

A: Official patient information leaflets define the frequency of reported side effects according to specific categories.

A 'Rare' side effect is classified as one that may be expected to affect up to 1 in every 1,000 people who use the medicine.

Q: What kind of monitoring might a doctor mention when a person is using Meralys?

A: Official guidance sets forth a review period, stating that contact with a doctor is indicated if symptoms worsen or do not show improvement within 3 to 7 days of beginning treatment.

This duration establishes a necessary short-term monitoring period for the treatment’s effectiveness.

Q: How quickly can someone generally expect Meralys to start working?

A: Regulatory-supported documentation states that the active ingredient is rapid-acting.

It is generally expected to begin to take effect and provide relief from congestion within approximately two minutes of being administered.

Q: Does taking Meralys affect the ability to drive or operate machinery?

A: Official product safety information indicates that the active substance has no or negligible influence on the ability to drive or use machines.

However, if effects like dizziness or visual disturbances are experienced, official documents note that caution is warranted.

Q: What if I forget to take a dose of Meralys—what do official sources say about what to do?

A: Regulatory guidance for a missed dose is included in the product information.

These instructions state that if the medicine is used regularly, the missed dose is taken as soon as it is remembered. However, if the time is close to the next scheduled dose, official instructions describe skipping the missed dose. The documentation notes that extra medication is not to be used to compensate for a forgotten dose.

Q: Can women who are planning pregnancy use Meralys?

A: The official regulatory information states that the product should not be used during pregnancy or when actively planning to conceive.

Use is generally reserved for situations where a doctor has specifically recommended it after careful consideration.

Q: Are there different strengths of Meralys available?

A: Yes, regulatory documents confirm that the active substance is available in at least two different concentrations of nasal spray solution.

These typically include a 0.5 mg/ml strength and a 1 mg/ml strength, with each concentration being designated for use in specific age groups.

Q: Does Meralys interact with common pain relievers?

A: Regulatory information has been checked for interactions with common pain relievers.

Data indicates that no known interactions were found between the active substance and common over-the-counter pain relievers, such as Paracetamol (acetaminophen).

Q: Does Meralys affect sleep patterns?

A: The official side effect profile for the active substance lists several potential effects related to sleep.

These include rare occurrences of insomnia (difficulty sleeping) and very rare reports of sleepiness or drowsiness. Nervousness is also listed as a potential effect that could influence sleep.

Q: What if Meralys does not seem to work for me?

A: Official regulatory information specifies seeking medical advice from a doctor or pharmacist if symptoms worsen after starting treatment.

Contact with a healthcare professional is also indicated if your symptoms do not improve within 3 to 7 days of use.

Q: Is there a generic version of Meralys available?

A: Meralys is a brand name for the active ingredient xylometazoline.

Since xylometazoline is widely used in medicine, regulatory-related sources confirm that the active ingredient itself is generally available as a generic medication.

Q: Do clinical trials on Meralys include people with pre-existing conditions?

A: The product’s official warnings specifically require caution for patients who have pre-existing medical conditions.

These conditions include heart disease, high blood pressure, and diabetes, suggesting that these populations were considered during the safety and efficacy evaluations for the medicine.

Q: Are there special warnings for people with kidney or liver problems using Meralys?

A: The official warnings and precautions section advises caution for individuals with known liver or kidney disease.

The regulatory documentation indicates that consultation with a doctor is necessary before use if you have these conditions.

Q: What is the role of Meralys in the overall treatment plan for the condition?

A: Regulatory sources clearly describe the primary purpose of the drug.

The active substance's role is to provide short-term symptomatic relief of nasal congestion. It is not intended to be a long-term treatment or cure for the underlying condition.

Q: What is the official patient information leaflet for Meralys called?

A: The official document containing detailed consumer information about the medicine is referred to by regulatory authorities as the 'Patient Information Leaflet (PIL)' or 'Package Leaflet.'

This document is included inside the product packaging and contains the approved information on how to use the medicine.

Q: Are there known effects of Meralys on mood or mental clarity?

A: The side effect profile for the active substance includes certain central nervous system effects.

These very rare effects, particularly in children, include reports of nervousness and hallucinations. These effects are considered to be related to mood and mental state.

How to Store and Dispose of Meralys?

Storage Requirements

Meralys (xylometazoline hydrochloride) must be stored below 25 C and kept from freezing to maintain its stability. The nasal spray must be protected from light and stored in its original container, which should be kept tightly closed and in an upright position. For child safety, the medicine must be stored out of the sight and reach of children.

In-Use Stability and Disposal

The product must be used within 28 days after first opening the bottle, regardless of remaining contents. Expired or unused Meralys must be disposed of properly; it must not be thrown away via wastewater or household waste. The user should ask a pharmacist for the correct procedure to dispose of the medicine according to local regulations.